Multinationals Look To M&A As Key China Growth Driver
This article was originally published in PharmAsia News
Mergers and acquisitions have been highlighted as key drivers of growth for pharma companies in China as domestic companies look to expand globally and multinationals attempt to localize.
You may also be interested in...
Suzhou-based Innovent Bio becomes the fourth biotech from mainland China to go public in Hong Kong, and its strong first-day performance may have given the seemingly spooked market so far for such companies a shot of confidence.
A rapidly reforming policy and regulatory environment and a growing culture of innovation are encouraging capital and talent to pour into China, making it a question of when, rather than if, the payoffs will come for both consumers and investors.